 | |
- close
- close
| |||||||||
Industry (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
 |
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
 |
|
| Operating Income | |
0 | 0 | 0 | 0 | 0 | |
|
| Gross Profit | |
11.2B | 11.9B | 12.9B | 15.4B | 17.1B | |
|
| Total Revenues | |
13.9B | 14.6B | 15.7B | 18.6B | 20.4B | |
|
| Net Income | |
1.81B | 1.98B | 2.66B | 2.95B | -2.07B | |
|
| Gross Margin | |
76.7% | 76.3% | 77.4% | 77.2% | 78.5% |   | |
| Research and Development Expense | |
2.69B | 3.03B | 3.13B | 3.49B | 3.84B | | |
| R&D/Sales Ratio | |
19.4% | 20.7% | 19.9% | 18.7% | 18.9% | | |
| Number of Patents | |
0 | 0 | 10.0 | 10.0 | 9.00 | | |
| Patents to Expire in next 5 years | |
0 | 2.00 | 2.00 | 4.00 | 5.00 | | |
| Number of Drugs | |
0 | 0 | 0 | 45.0 | 60.0 | | |
| Return on Equity | |
0% | 0% | 0% | 24.3% | -16.3% | | |
| ||||||
|
|
